The anti-cancer drug abemaciclib (also known as Vernezio) has this month been added to the Australian Pharmaceutical Benefits Scheme (PBS)...
5 months ago

For the first time in 15-years women with an invasive form of early breast cancer that has a high risk of returning after initial treatment...
5 months ago

The benefit of axillary lymph node dissection in those with two positive sentinel nodes should be evaluated on a case-by-case basis.
8 months ago

Abemaciclib will be available for reimbursement for people with high-risk oestrogen-driven breast cancer in Ireland from June 1.
4 months ago

Dr Priya Hays, Ph.D., CEO/Science Writer at Hays Documentation Specialists, LLC, responds to “Tyranny of the Gene.”
10 months ago

Reversal of earlier rejection by Nice of abemaciclib – known as Verzenios – is welcomed by campaigners.
37 months ago

Japanese regulatory authorities have announced a set of additional reimbursement price cuts for selected products in August, under which Novartis's heart...
12 months ago

Last October, England's drug-cost watchdogs dealt Eli Lilly a blow when they decreed that the company's CDK 4/6 inhibitor to treat breast...
68 months ago

Drugmaker, Eli Lilly and Company (India), said that its breast cancer drug, Ramiven (abemaciclib), has got regulatory approval for the additional indication of...
22 months ago

Abemaciclib can improve chances of certain type of cancer not returning after surgery by more than 30%
27 months ago